Role of IL-37 in Inflammatory Skin Diseases and Its Regulatory Mechanism via Aryl Hydrocarbon Receptor

DOI HANDLE Web Site Open Access
  • TSUJI Gaku
    Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital

Bibliographic Information

Other Title
  • 炎症性皮膚疾患におけるIL-37の役割と芳香族炭化水素受容体による制御機構
  • エンショウセイ ヒフ シッカン ニ オケル IL-37 ノ ヤクワリ ト ホウコウゾク タンカスイソ ジュヨウタイ ニ ヨル セイギョ キコウ

Search this article

Abstract

Interleukin (IL)-37 has been identified as an anti-inflammatory cytokine with the ability to suppress inflammation. However, its role remains largely unknown. Recent studies suggest that IL-37 may be a potential new therapeutic target in the treatment of inflammatory skin diseases. It has been shown that the dioxin receptor, the aryl hydrocarbon receptor (AHR), is involved in the pathogenesis of inflammatory skin diseases. In this article, we present the latest findings on the relationship between IL-37 and AHR in inflammatory skin diseases, including our studies. IL-37 is expressed in the granular layer of the skin, together with skin barrier function proteins such as Filaggrin, Loricrin and Involucrin. In lesions of atopic dermatitis and psoriasis, these skin barrier proteins are reduced, consistent with decreased expression of IL-37. We analyzed the expression of IL-37 in normal human epidermal keratinocytes treated with an AHR modulator that promotes keratinocyte differentiation. The therapeutic AHR- modulating agent, Tapinarof, induced IL-37 expression, which mechanism was AHR-dependent. We have revealed that the AHR is the receptor that regulates the expression of IL-37 in the skin. Thus, tapinarof potentially exerts a broad anti-inflammatory effect by inducing IL-37 and is expected to have novel therapeutic effects on inflammatory skin diseases.

Journal

  • 福岡醫學雜誌

    福岡醫學雜誌 114 (1), 3-9, 2023-03-25

    Fukuoka Medical Association

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top